ClinicalTrials.gg
CompletedNCT04383938Updated May 13, 2025Results posted

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

A Phase 1/2 interventional study of APR-246 (eprenetapopt) + Pembrolizumab in Bladder Cancer, Gastric Cancer and Non Small Cell Lung Cancer, sponsored by Aprea Therapeutics. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-13.

Primary conditionnone(registry's first term: Urinary Bladder Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Urinary Bladder Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Aprea Therapeutics · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies. The study will include a safety lead-in portion followed by a phase 2 expansion portion in specific disease groups.

Read the detailed description

This is a phase 1/2, open-label, study to determine the safety and preliminary efficacy of APR-246 (eprenetapopt) in combination with pembrolizumab in subjects with solid tumor malignancies. In the safety lead-in part of study (phase 1), the safety and the recommended phase 2 dose (RP2D) of APR-246 will be investigated.

In the expansion part of the study (phase 2), both safety and efficacy for the combination therapy will be investigated in the 3 cohorts.

02

Conditions studied

  • Bladder Cancer
  • Gastric Cancer
  • Non Small Cell Lung Cancer
  • NSCLC
  • Urothelial Carcinoma
  • Advanced Solid Tumor

Keywords

  • Pembrolizumab
  • APR-246
  • Aprea
  • eprenetapopt
03

In context

Lead sponsor

Aprea Therapeutics is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form (ICF) and ability to comply with protocol requirements.
  2. Known tumor TP53 mutation status from recent or .
  3. and/or cytologically confirmed solid tumor

    1. Safety lead in- Advanced non-central nervous system (CNS) primary tumors that have progressed after treatment, who are intolerant to first line treatment, or who are unable to receive first line treatment, and for whom pembrolizumab, or pembrolizumab-based therapy is considered appropriate
    2. Expansion 1- Patients with a confirmed diagnosis of advanced gastric or gastroesophageal junction (GEJ) tumors that have progressed after first line treatment, who are intolerant to first line treatment, or who are unable to receive first line treatment
    3. Expansion 2- Patients with a confirmed diagnosis of advanced bladder/urothelial tumors that have progressed after first line treatment, or who are intolerant to first line treatment, or who are unable to receive first line treatment with cisplatin-based chemotherapy.
    4. Expansion 3- Confirmed diagnosis of advanced non-small cell lung cancer (NSCLC) previously treated with or anti-PD-L1 therapy.
  4. Adequate organ function

    1. > 30 mL/min
    2. Total serum \< 1.5 × (ULN) unless due to Gilbert's syndrome, tumor involvement, hemolysis or considered an effect of regular blood transfusions
    3. (ALT) and aspartate aminotransferase (AST) \< 3 × ULN, unless due to involvement by the underlying malignancy.
  5. Projected of ≥ 12 weeks.
  6. Age ≥ 18 years at the time of signing the ICF.
  7. (ECOG) performance status of 0, 1 or 2
  8. In the expansion portion, meeting the following criteria:

    1. At least 1 lesion of ≥10 mm in the longest diameter (LD) for a non-lymph node or ≥15 mm in the short-axis diameter for a lymph node that is serially measurable according to 1.1.
    2. Lesions that have had external beam radiotherapy or loco-regional therapies such as radiofrequency ablation must show subsequent evidence of substantial size increase (ex. 20% increase in LD) to be deemed a target lesion.
  9. Negative serum or urine pregnancy test prior to study treatment initiation in female subjects of .
  10. Women of childbearing potential and men with female partners of childbearing potential must be willing to use an effective form of

Exclusion criteria

Exclusion Criteria:

  1. Known history of untreated (HIV)/HIV with a detectable viral load or active or active infection.
  2. Cardiac abnormalities
  3. Concomitant or previous malignancies with less than a 1-year disease-free interval at the time of signing consent.
  4. Pregnancy or lactation.
  5. Active uncontrolled systemic infection.
  6. An condition requiring ≥ 10 mg (or equivalent ) prednisone daily, or any other systemic treatment within 28 days of first dose of study therapy.
  7. Known history of active tuberculosis.
  8. Current (non-infectious) pneumonitis, or a history of pneumonitis that required steroids.
  9. A administered within 30 days of the first dose of study treatment.
  10. Receipt of any product within 14 days or 5 half-lives prior to study treatment initiation, whichever is shortest.
  11. Prior intolerance to pembrolizumab or other /PD-L1 agents.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Safety Lead In-Phase 1 Dose Level 1

    APR-246 4.5g/d with pembrolizumab 200 mg IV (day 3) every 21 days in patients with advanced non-CNS primary tumors

    Drug: APR-246 (eprenetapopt) + Pembrolizumab

  • Experimental
    Expansion 1- Gastric Cancer

    APR-246 4.5 g/d (days 1-4) with pembrolizumab 200 mg IV (day 3) every 21 days in patients with advanced gastric or GEJ tumors

    Drug: APR-246 (eprenetapopt) + Pembrolizumab

  • Experimental
    Expansion 2- Bladder Cancer

    APR-246 4.5 g/d (days 1-4) with pembrolizumab 200 mg IV (day 3) every 21 days in patients with advanced bladder or urothelial tumors

    Drug: APR-246 (eprenetapopt) + Pembrolizumab

  • Experimental
    Expansion 3 -NSCLC

    APR-246 4.5 g/d (days 1-4) with pembrolizumab 200 mg IV (day 3) every 21 days in patients with advanced NSCLC.

    Drug: APR-246 (eprenetapopt) + Pembrolizumab

Interventions

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors.

    To determine the Frequency of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs) related to APR-246 in combination with pembrolizumab.

    Time frame: Through study completion, approximately 1 year

  2. To Confirm the Recommended Phase 2 Dose (RP2D) for APR-246 in Combination With Pembrolizumab

    To determine the dose of APR-246 to be selected for the expansion phase based on the occurence of dose limiting toxicities (DLTs) experienced during the safety assessment period

    Time frame: Through safety lead in period, during cycle 1 (approximately 21 days)

07

Results

Posted May 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneExperimental: Safety Lead InExperimental: Expansion 1Experimental: Expansion 2Experimental: Expansion 3
Started68521
Completed66520
Not completed0201

Outcome measures

PrimaryTo Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors.

To determine the Frequency of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs) related to APR-246 in combination with pembrolizumab.

Time frame:
Through study completion, approximately 1 year
Reported as:
Number · participants
To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors.
participantsExperimental: Safety Lead InExperimental: Expansion 1Experimental: Expansion 2Experimental: Expansion 3
To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors.66520
PrimaryTo Confirm the Recommended Phase 2 Dose (RP2D) for APR-246 in Combination With Pembrolizumab

To determine the dose of APR-246 to be selected for the expansion phase based on the occurence of dose limiting toxicities (DLTs) experienced during the safety assessment period

Time frame:
Through safety lead in period, during cycle 1 (approximately 21 days)
Reported as:
Number · g/d
To Confirm the Recommended Phase 2 Dose (RP2D) for APR-246 in Combination With Pembrolizumab
g/dExperimental: Safety Lead In
To Confirm the Recommended Phase 2 Dose (RP2D) for APR-246 in Combination With Pembrolizumab4.5

Adverse events

Collected over 13 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Safety Lead In5/6 (83.3%)1/6 (16.7%)6/6 (100%)
Experimental: Expansion 14/6 (66.7%)4/6 (66.7%)5/6 (83.3%)
Experimental: Expansion 22/5 (40%)3/5 (60%)5/5 (100%)
Experimental: Expansion 310/20 (50%)7/20 (35%)20/20 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventExperimental: Safety Lead InExperimental: Expansion 1Experimental: Expansion 2Experimental: Expansion 3
PainGeneral disorders0/61/61/50/20
Abdominal PainGastrointestinal disorders1/60/61/50/20
Abdominal pain lowerGastrointestinal disorders0/60/61/50/20
NauseaGastrointestinal disorders0/60/61/50/20
HypotensionVascular disorders0/60/61/51/20
Pelvic PainReproductive system and breast disorders0/60/61/50/20
Disease ProgressionGeneral disorders1/61/60/50/20
Abdominal Pain upperGastrointestinal disorders1/60/60/50/20
EmbolismVascular disorders0/61/60/50/20
Acute Kidney InjuryRenal and urinary disorders0/61/60/50/20
Most frequent other events
Showing 10 of 57
Most frequent other events
EventExperimental: Safety Lead InExperimental: Expansion 1Experimental: Expansion 2Experimental: Expansion 3
NasueaGastrointestinal disorders3/62/64/56/20
VomitingGastrointestinal disorders1/61/64/56/20
DizzinessNervous system disorders1/61/64/59/20
FatigueGeneral disorders4/61/64/53/20
AnaemiaBlood and lymphatic system disorders1/61/64/53/20
Abdominal PainGastrointestinal disorders4/60/63/51/20
Blood alkaline phosphatase increasedInvestigations4/60/61/52/20
ConstipationGastrointestinal disorders1/61/63/55/20
DiarrheaGastrointestinal disorders0/62/63/52/20
MyalgiaMusculoskeletal and connective tissue disorders0/60/63/51/20

Baseline characteristics

Baseline characteristics are presented by cohort.

Age, Continuous
Age, Continuous(years)Experimental: Safety Lead InExperimental: Expansion 1 Patients With Advanced Gastric Cancer.Experimental: Expansion 2Experimental: Expansion 3 Patients With Advanced NSCLCTotal
Median58 (35 to 85)67 (27 to 79)67 (55 to 75)67 (54 to 85)66 (27 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Safety Lead InExperimental: Expansion 1 Patients With Advanced Gastric Cancer.Experimental: Expansion 2Experimental: Expansion 3 Patients With Advanced NSCLCTotal
Female2111317
Male474823
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Safety Lead InExperimental: Expansion 1 Patients With Advanced Gastric Cancer.Experimental: Expansion 2Experimental: Expansion 3 Patients With Advanced NSCLCTotal
American Indian or Alaska Native00000
Asian10113
Native Hawaiian or Other Pacific Islander00000
Black or African American00044
White5731631
More than one race00000
Unknown or Not Reported01102
Region of Enrollment
Region of Enrollment(participants)Experimental: Safety Lead InExperimental: Expansion 1 Patients With Advanced Gastric Cancer.Experimental: Expansion 2Experimental: Expansion 3 Patients With Advanced NSCLCTotal
United States6852140
08

Study locations

8 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Center
    Boston, Massachusetts 02115, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Washington University
    Saint Louis, Missouri 63130, United States
  • Vanderbilt University
    Nashville, Tennessee 37235, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, Singh P, Ahrorov A, Gandhi L, Ghosh A, Hickman D, Gallacher PD, Wennborg A, Attar EC, Awad MM, Das S, Dumbrava EE. Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022 Oct;7(5):100573. doi: 10.1016/j.esmoop.2022.100573. Epub 2022 Sep 7. PubMed 36084396 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Apr 2022, 22 months.

Results were first posted in May 2025, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2020
First posted
May 12, 2020
StartActual
Jun 25, 2020
Primary completionActual
Apr 30, 2022
CompletionActual
Apr 30, 2022
Results first posted
May 13, 2025
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04383938
Lead sponsor
Aprea Therapeutics
Responsible party
Sponsor
First posted
May 12, 2020
Start date
Jun 25, 2020
Primary completion
Apr 30, 2022
Completion
Apr 30, 2022
Results posted
May 13, 2025
Last update
May 13, 2025

Study contacts

Joachim Gullbo, MD
study director · Theradex Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eprenetapopt

Start the discussion